BPMX:NYE-BioPharmX Corporation (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.51

Change

0.00 (0.00)%

Market Cap

USD 0.78M

Volume

3.91M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trials for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of papulopustular rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in Campbell, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

USD160.33B 24.87 2.76
ADPT Adaptive Biotechnologies Corpo..

N/A

USD6.29B 38.68 N/A
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD3.79B N/A N/A
ADCT ADC Therapeutics SA

N/A

USD3.19B -99,999.99 N/A
ZYME Zymeworks Inc

N/A

USD2.07B 300.20 N/A
MYOV Myovant Sciences Ltd

N/A

USD1.98B N/A N/A
RCUS Arcus Biosciences, Inc

N/A

USD1.54B N/A N/A
KDMN Kadmon Holdings, Inc

N/A

USD0.77B 2.20 N/A
CVM CEL-SCI Corporation

N/A

USD0.55B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90

ETFs Containing BPMX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.28% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.28% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 37.84% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.84% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.65% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.65% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.37% N/A N/A N/A N/A
Risk Adjusted Return 32.35% N/A N/A N/A N/A
Market Capitalization 0.78M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.90 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.08 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -2,020.23% N/A N/A N/A N/A
Return on Invested Capital -1,704.13% N/A N/A N/A N/A
Return on Assets -209.33% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.33 N/A N/A N/A N/A
Short Percent 6.80% N/A N/A N/A N/A
Beta 0.63 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.